Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon alpha2a.
Primary B cell lymphomas of the skin are rare disorders and therapy is not yet standardized. A 45-year-old male patient presented 4 years after surgical removal of a subcutaneous tumour of the leg. On examination a reddish nodular tumour was found in the same region. The biopsy revealed a T-cell-rich primary B cell lymphoma of the skin. Interferon alpha2a was given perilesionally at a dosage of 9 MU three times a week. The treatment was well tolerated, had no severe side-effects and induced a complete remission, both clinically and histologically, during a 12-months course.
Wollina
U
U
Department of Dermatology, Friedrich Schiller University of Jena, Germany. uwol@derma.uni-jena.de
D018951:Antigens, CD20 / Q000378:metabolism; D001706:Biopsy; D017252:CD3 Complex / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013601:T-Lymphocytes / Q000473:pathology*
D018951:Antigens, CD20; D017252:CD3 Complex; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins